Initial clinical experience with PSMA-617 began in 2014, demonstrating its potential for both diagnostic imaging and radioligand therapy in advanced PCa—a strategy now referred to as theranostics [127,128]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.